29d
Adding Eli Lilly’s R&D Chief to the Board Might Change The Case For Investing In Illumina (ILMN)
Illumina, Inc. recently expanded its Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research ...
Intro: Has Roche Just Eclipsed Eli Lilly In The Battle For AI Drug Development Supremacy? On Monday, 16th March, the Swiss Pharma giant Roche Holding AG (RHHBY) announced: an expansion of its global ...
SHANGHAI, June 23, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results